Current Neurology and Neuroscience Reports

, Volume 1, Issue 4, pp 329–336

Initial treatment of early Parkinson’s disease: A review of recent, randomized controlled trials

  • Kevin Biglan
  • Robert G. Holloway
Article

Abstract

Many studies have shown dopamine agonists to significantly improve parkinsonian symptoms compared with placebo in early Parkinson’s disease (PD), but how do agonists compare with the standard treatment of levodopa? Recently, three large, multicenter, randomized controlled studies directly comparing a dopamine agonist with levodopa as initial therapy in early PD have been published. These studies suggest that although both agents effectively ameliorate parkinsonian symptoms, levodopa was superior to dopamine agonists as measured by improvement in Unified Parkinson’s Disease Rating Scale (UPDRS) scores. However, levodopa was more frequently associated with dopaminergic motor complications, and the dopamine agonists were more commonly associated with adverse events. Until further studies clearly demonstrate the beneficial effects of one therapeutic strategy over another, the decision to initiate treatment in early PD with either an agonist or levodopa will be based on the favorable motor complication profile of agonists versus the more potent antiparkinsonian effects and the favorable side-effect profile of levodopa.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Clarke CE, Speller JM: Pergolide for levodopa-induced complications in Parkinson’s disease (Cochrane Review). The Cochrane Library 2000, (CD000235, 2000. Oxford: Update Software).Google Scholar
  2. 2.
    Kristensen O, Hansen E: Bromocriptine in the treatment of advanced parkisonism. Acta Neurol Scand 1977, 56:274–276.PubMedCrossRefGoogle Scholar
  3. 3.
    Shannon KM, Bennett JP, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group [published erratum appears in Neurology 1998 Mar; 50(3):838]. Neurology 1997, 49:724–728.PubMedGoogle Scholar
  4. 4.
    Adler CH, Sethi KD, Hauser RA, et al.: Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group [published erratum appears in Neurology 1997 Nov; 49(5):1484]. Neurology 1997, 49:393–399.PubMedGoogle Scholar
  5. 5.
    Sethi KD, O’Briend CF, Hammerstad JP, et al.: Ropinerole in the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol 1998, 55:1211–1216.PubMedCrossRefGoogle Scholar
  6. 6.
    Rinne UK: Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurology 1987, 45:519–523.Google Scholar
  7. 7.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson Disease. JAMA 2000, 284:1931–1938. A randomized controlled trial of pramipexole versus levodopa in patients with early Parkinson’s disease. It is the only study to systematically compare quality of life in one treatment over another.CrossRefGoogle Scholar
  8. 8.
    Rascol O, Brooks DJ, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484–1491. A randomized controlled trial of ropinirole versus levodopa in patients with early Parkinson’s disease. It was the only study to assess the severity of motor complications as judged by the patients; however, dyskinesias were the only dopaminergic motor complication evaluated.PubMedCrossRefGoogle Scholar
  9. 9.
    Rascol O, Brooks DJ, Brunt ER, et al.: Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998, 13:39–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Rinne UK, Bracco F, Chouza C, et al.: Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 2000, 48:363–368.Google Scholar
  11. 11.
    Rinne UK, Bracco F, Chouza C, et al.: Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. PKDS009 Collaborative Study Group. Drugs 1998, 1:23–30. A randomized controlled trial of cabergoline versus levodopa in early Parkinson’s disease. This study looked at the widest variety of dopaminergic motor complications. Unfortunately, cabergoline is not widely available, limiting the generalizability of the study.CrossRefGoogle Scholar
  12. 12.
    Guyatt GH, Sackett DL, Cook DJ: Evidence-Based Medicine Working Group. Users’ guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994, 271:59–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Parkinson Study Group. Safety and efficacy of pramipexole in early parkinson disease: a randomized dose-ranging study. JAMA 1997, 278:125–130.CrossRefGoogle Scholar
  14. 14.
    Ling LH, Ahlskog JE, Munger TM, et al.: Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc 1999, 74:371–375.PubMedGoogle Scholar
  15. 15.
    Welsh M, McDermott M, Holloway R, et al.: Development and testing of the parkinson’s disease quality of life scale: the PDQUALIF. Mov Disord 1997, 12:836.CrossRefGoogle Scholar
  16. 16.
    EuroQol Group. EuroQol-A new facility for the measurement of health related quality of life. Health Policy 1990, 12:199–208.Google Scholar
  17. 17.
    Fahn S: Is levodopa toxic? Neurology 1996, 47(suppl 3):184–195.Google Scholar
  18. 18.
    Agid Y: Levodopa. Is toxicity a myth? Neurology 1998, 50:858–863.PubMedGoogle Scholar
  19. 19.
    Weiner WJ: Is levodopa toxic? Controversies in neurology. Arch Neurol 2000, 57:408–410.PubMedCrossRefGoogle Scholar
  20. 20.
    Fahn S: Parkinson disease, the effect of levodopa and the ELLDOPA trial. Arch Neurol 1999, 56:535.Google Scholar
  21. 21.
    Yahr MD, Wolf A, Antunes J, et al.: Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972, (suppl):56–71.Google Scholar
  22. 22.
    Yamamoto M: Do dopamine agonists provide neuroprotection? [review]. Neurology 1998, 51(suppl 2):S10-S12.PubMedGoogle Scholar
  23. 23.
    Ogawa N: Early introduction of dopamine agonists in the long-term treatment of Parkinson’s disease [review]. Neurology 1998, 51(suppl 2):S13-S20. This paper is an excellent review of the clinical, experimental, and theoretical arguments favoring the use of dopamine agonists in the treatment of early Parkinson’s disease.PubMedGoogle Scholar
  24. 24.
    Rakshi JS, Bailey DL, Uema T, et al.: Is ropinirole, a selective D2 receptor agonist, neuro-protective in early Parkinson’s disease? An [18F]dopa PET study. Neurology 1998, 59:A330.Google Scholar
  25. 25.
    Poewe W: Should treatment of Parkinson’s disease be started with a dopamine agonist? [review]. Neurology 1998, 51(suppl 2):S21-S24.PubMedGoogle Scholar
  26. 26.
    1998 Drug Topics Red Book. Montvale, NJ: Medical Economics Data Company, 1998.Google Scholar
  27. 27.
    Korczyn AD, Brunt ER, Larsen JP, et al.: A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology 1999, 53:364–370.PubMedGoogle Scholar
  28. 28.
    Montastruc JL, Rascol O, Senard JM, Rascol A: A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994, 57:1034–1038.PubMedGoogle Scholar
  29. 29.
    Hely MA, Morris JG, Reid WG, et al.: The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903–910.PubMedGoogle Scholar
  30. 30.
    Carrion A, Weiner WJ, Shulman LM: A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early parkinson’s disease. Neurology 1998, 50:A330.Google Scholar
  31. 31.
    Schrag A, Ben-Shlomo Y, Brown R, et al.: Young-onset Parkinson’s disease revisited—clinical features, natural history, and mortality. Mov Disord 1998, 13:885–894.PubMedCrossRefGoogle Scholar
  32. 32.
    Grandas F, Galiano ML, Tabernero C: Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol 1999, 246:1127–1133.PubMedCrossRefGoogle Scholar
  33. 33.
    Friedman A: Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 1994, 89:258–261.PubMedCrossRefGoogle Scholar
  34. 34.
    Montastruc JL, Rascol O, Rascol A: A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989, 52:773–775.PubMedCrossRefGoogle Scholar
  35. 35.
    Hely MA, Morris JG, Rail D, et al.: The Sydney Multicentre Study of Parkinson’s disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989, 52:324–328.PubMedGoogle Scholar
  36. 36.
    Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson’s disease: a population based, prospective study. J Am Geriatr Soc 2000, 48:938–942.PubMedGoogle Scholar
  37. 37.
    Giladi N, Treves TA, Paleacu D, et al.: Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J Neural Transmission (Budapest) 2000, 107:59–71.CrossRefGoogle Scholar
  38. 38.
    Frucht S, Rogers JD, Green PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908–1910.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Kevin Biglan
    • 1
  • Robert G. Holloway
    • 1
  1. 1.Department of NeurologyUniversity of RochesterRochesterUSA

Personalised recommendations